Zacks Investment Research upgraded shares of ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) from a sell rating to a hold rating in a research report report published on Friday.
According to Zacks, “ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory....More>>>
Krystal Biotech (NASDAQ:KRYS) and Coherus Biosciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.
Insider & Institutional Ownership
Get Krystal Biotech alerts:....More>>>
NanoString Technologies Inc (NASDAQ:NSTG) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. NanoString Technologies Inc is a biotechnology company. It develops, manufactures and sells products that unlock scientifically valuable and clinically actionable genomic information from minute amounts of tissue. NanoString Technologies Inc has a market cap of $916.930 million;....More>>>
Trexquant Investment LP raised its stake in shares of ImmunoGen (NASDAQ:IMGN) by 190.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 331,215 shares of the biotechnology company’s stock after buying an additional 217,244 shares during the quarter. Trexquant Investment LP owned about 0.25% of ImmunoGen worth $3,484,000....More>>>
Shares of Verastem (NASDAQ:VSTM) are up 16% in late-day trading on Friday after the company announced yesterday after the bell that it was selling 7,166,666 shares at $6 per share, grossing the biotech approximately $43 million.
Share prices typically — though clearly not always — go down after a secondary offering is announced, since current....More>>>
Quantitative Systematic Strategies LLC bought a new stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 13,931 shares of the biotechnology company’s stock, valued at approximately $100,000.
Several other large investors also recently added....More>>>
Puma Biotechnology (NASDAQ:PBYI) ended the day down 13.8% after Roche (NASDAQOTH:RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed “Aphinity.”
Image source: Getty Images.
In Roche’s trial, patients either took Perjeta and Herceptin with chemotherapy or just Herceptin with chemotherapy,....More>>>
The meteoric run up in cryptocurrency valuations last year looked every bit a speculative bubble as the dot-com craze 20 years ago, and the subsequent implosion of valuations in the months since has deepened the parallels. A recent Bloomberg story noted that hundreds of virtual coins have gone to practically zero in value as the market crashed.
Although some tokens will continue to offer....More>>>
The short interest data are out for the most recent settlement date, June 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside.
As we have said before, FDA rulings can make or break the biotech stocks, and short sellers and mega-bulls often go to war against each other in these companies.....More>>>
Fluidigm (NASDAQ:FLDM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.
According to Zacks, “Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD....More>>>
Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep up with recent events in the biotech and pharmaceutical industries!
So what’s in store for today?
BioMarin makes itself a priority to the FDA in phenylketonuria
Phenylketonuria is a congenital disorder that can lead to severe complications....More>>>
Before explaining and updating my version of the Celgene (NASDAQ:CELG) story, first, I’ll briefly explain and link to the 2 1/2-year story of my bullish-bearish-bullish evolution of views on this stock. This will help lay the groundwork to why I am again accentuating the positives, understanding there are negatives; the article goes into both sides of the CELG argument.
Human understanding of biology is progressing like never before. Those advancements could ultimately help millions of humans live longer, better lives. For investors, the companies that are helping to move the ball forward could create vast wealth for their shareholders.
With that in mind, we asked a team of Motley Fool investors to highlight a biotech stock that they think is a strong....More>>>
A staggering amount of money is flowing into new companies with promising new technologies, many of which will lead to innovative new drugs. There have been 32 biotech IPOs on the Nasdaq exchange in 2018, and dozens more have raised nine-figure sums privately.
The recent surge in biotech investment is terrific for the pace of innovation, but that capital isn’t heading toward the industry’s....More>>>
DekaBank Deutsche Girozentrale acquired a new stake in shares of Uniqure NV (NASDAQ:QURE) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,600 shares of the biotechnology company’s stock, valued at approximately $299,000.
A number of other institutional investors and hedge funds also recently made....More>>>